Rheumatoid arthritis: Can tofacitinib be used as first-line monotherapy for RA? (Nature Clinical Practice Rheumatology)

The Janus kinase inhibitor tofacitinib was originally approved by the FDA for use in patients with rheumatoid arthritis (RA) who did not achieve a sufficient response to (or who did not tolerate) methotrexate, the most widely used antirheumatic drug. However, the 24-month results of the